Theoretical benefit via IL-6 pathway inhibition exists for inflammatory myocarditis subtypes, but the absence of safety/efficacy data in EMB-proven cases contraindicates off-label use per the 2025 ESC guidelines. The gene discussed is IL6; the disease is myocarditis.